DEA Raises 2027 Psychedelic Quotas, Teases Separate Marijuana Plan

The Drug Enforcement Administration is moving to significantly expand how much of certain psychedelic substances can be legally manufactured in the United States next year. The increase would apply to production for medical, scientific, research and industrial purposes, and it signals that federal officials expect demand for these compounds in legitimate channels to keep climbing.

Production quotas are the annual limits the DEA sets on how much of a controlled substance can be made domestically. They act as a gatekeeper for researchers, drug developers and manufacturers, since companies can only work with the amounts the agency allows. When the agency raises those numbers sharply, it can ease supply constraints that have slowed some studies and early-stage product development.

The notice also carried a second piece of news that matters to the cannabis world. The agency said it plans to issue a separate proposal to set marijuana production quotas, reflecting the Trump administration's rescheduling move. That means marijuana is not folded into the current quota announcement, and the details of how much cannabis could be produced under the federal system will come later in its own rulemaking.

That preview is notable because rescheduling changes how the government classifies marijuana, and quota-setting is one of the mechanisms that follows from classification under the Controlled Substances Act. How the agency approaches cannabis quotas could shape who is allowed to produce it for federally authorized purposes and in what volumes, though the specifics have not yet been laid out.

For now, the psychedelic quota increase is the concrete action, while the marijuana proposal remains a promise. Researchers and companies working with psychedelics will be watching how the final quotas land, and cannabis stakeholders will be watching for the separate notice to see how the agency translates rescheduling into real production numbers.